EPS for OptiNose, Inc. (OPTN) Expected At $-0.74 on June, 12

May 17, 2018 - By Jenna Rose

Earnings report for OptiNose, Inc. (NASDAQ:OPTN) is expected on June, 12., as reported by RTT. 15.63 % negative EPS growth is what analysts predict. $-0.64 EPS was reported for previous quarter. Ticker’s shares touched $24.58 during the last trading session after 4.51% change.OptiNose, Inc. has 597,935 shares volume, 618.64% up from normal. OPTN is and has moved 0.00% since May 17, 2017. The stock underperformed the S&P 500 by 11.55%.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.The firm is valued at $931.81 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.Currently it has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

For more OptiNose, Inc. (NASDAQ:OPTN) news released briefly go to: Nasdaq.com, Digitaljournal.com, Nasdaq.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in …” released on April 23, 2018, “OptiNose, Inc. to Host Earnings Call” on May 14, 2018, “Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights” with a publish date: May 14, 2018, “Optinose (OPTN) PT Raised to $30 at BMO Capital” and the last “OptiNose, Inc. 2018 Q1 – Results – Earnings Call Slides” with publication date: May 14, 2018.

OptiNose, Inc. (NASDAQ:OPTN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.